Name | BT-13 |
---|
Description | BT-13 is a potent and selective glial cell line-derived neurotrophic factor (GDNF) receptor RET agonist independently of GFLs, promoting neurite growth from sensory neurons in vitro and attenuates experimental neuropathy in the Rat[1]. |
---|---|
Related Catalog | |
Target |
GDNF receptor RET[1]. |
In Vitro | BT-13 stimulates phosphorylation of RET, as well as RET-dependent intracellular signaling, but activated neither NGF receptor TrkA nor BDNF receptor TrkB nor intracellular signaling in the absence of RET[1]. |
In Vivo | BT-13 (20 and 25mg/kg in rats induced by ligation of left L5 and L6 spinal nerves) has a slight antinociceptive/antihyperalgesic effect and protected DRG neurons in rats with surgery-induced neuropathy[1]. Animal Model: Rats induced by ligation of left L5 and L6 spinal nerves[1]. Dosage: 5-25 mg/kg, dissolved in sesame oil containing 5% DMSO. Administration: Subcutaneous injections on post-surgical day 1, 3, 5, 8, 10, and 12. Result: 20 and 25mg/kg decreased mechanical hypersensitivity and normalized expression of sensory neuron markers in dorsal root ganglia. |
References |
Molecular Formula | C23H27F4N3O4S |
---|---|
Molecular Weight | 517.54 |
Storage condition | 2-8°C |